We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Syros Pharmaceuticals Inc | NASDAQ:SYRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.15 | -2.91% | 5.00 | 4.71 | 5.03 | 5.23 | 4.94 | 5.13 | 67,056 | 01:00:00 |
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:
JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY
TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Wednesday, May 29 Presentation Time: 1:00 p.m. ET Location: Virtual
To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/
Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com
Investor Contact Amanda Isacoff Stern Investor Relations, Inc. 212-362-1200 amanda.isacoff@sternir.com
1 Year Syros Pharmaceuticals Chart |
1 Month Syros Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
